IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors
03 Ottobre 2023 - 10:05PM
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage
biotechnology company focused on creating and developing engineered
IgM antibodies, today announced that Michael Loberg, Ph.D. has
retired from its Board of Directors, including as Chairman,
effective October 3, 2023. Dr. Loberg has served as a member of the
IGM Biosciences Board of Directors since 2015 and as Chairman of
the Board since 2018.
IGM Biosciences is also pleased to announce the
appointment of Elizabeth H.Z. Thompson, Ph.D. to its Board of
Directors. Dr. Thompson is an accomplished drug development
professional who has been involved in the development of important
marketed medicines, most recently as the Executive Vice President
of Research and Development at Horizon Therapeutics.
“Dr. Loberg has played a pivotal role in the
development of IGM Biosciences over the last eight years,” said
Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “As a
member and Chairman of our Board of Directors, he has provided
vital strategic advice and guidance through the creation, research
and initial clinical development of our IgM based antibody platform
and through multiple private and public equity financings,
including our initial public offering, as well as our strategic
partnership with Sanofi. We are very grateful for his leadership
and contributions, and we have greatly enjoyed working together
with him to advance our shared vision of broadly developing the
potential of IgM antibodies to treat unmet medical needs.”
Dr. Thompson currently serves as Executive Vice
President of Research and Development at Horizon Therapeutics. She
is also a member of the board of California Life Sciences, an
influential life sciences membership organization. At Horizon, Dr.
Thompson is responsible for overseeing all research and development
activities across the company's preclinical, clinical and marketed
products. She played an important role in the acquisition and
integration of Viela Bio as well as the expedited filing and
approval of TEPEZZA®, along with its successful FDA Advisory
Committee meeting.
Dr. Thompson previously served as a Group
Scientific Director in pharmaceutical development at AbbVie, acting
as clinical lead and supporting global submissions and approvals
for SKYRIZI®. She previously held positions across the clinical
development, business development and medical communications fields
as Search and Evaluation Lead at Raptor Pharmaceuticals, Head of
Scientific Communications and Publications at InterMune and
Development Clinical Director and Licensing Director at Amgen.
Dr. Thompson holds a Ph.D. in Macromolecular and
Cellular Structure and Chemistry from the Scripps Research
Institute and a B.S. in Chemistry from Harvey Mudd College.
“We are honored to welcome Dr. Thompson to our
Board of Directors at this exciting point in IGM’s development,”
said Mr. Schwarzer. “As we move forward with our two recently
initiated Phase 1b trials of imvotamab in systemic lupus
erythematosus and severe rheumatoid arthritis and continue to
develop our broad pipeline of products in oncology, we are
confident that Dr. Thompson’s expertise in research, clinical
development and operations as well as her insights in business
development and medical communications will greatly benefit
IGM.”
“IGM Biosciences is an exciting and innovative
company developing unique approaches in multiple therapeutic areas
using IgM antibodies,” said Dr. Thompson. “I am pleased to join IGM
at this important stage of its development, and I look forward to
using my knowledge and experience to assist in the continued
development of IGM’s clinical pipeline, including in the promising
new field of applying T cell engager technology to autoimmune
diseases.”
About IGM Biosciences, Inc.IGM Biosciences is a
clinical-stage biotechnology company committed to developing and
delivering a new class of medicines to treat patients with cancer,
autoimmune and inflammatory diseases and infectious diseases. IGM’s
pipeline of clinical and preclinical assets is based on the IgM
antibody, which has 10 binding sites compared to conventional IgG
antibodies with only 2 binding sites. IGM also has an exclusive
worldwide collaboration agreement with Sanofi to create, develop,
manufacture, and commercialize IgM antibody agonists against
oncology and immunology and inflammation targets. For more
information, please visit www.igmbio.com.
Contact:Argot PartnersDavid
Pitts212-600-1902igmbio@argotpartners.com
Grafico Azioni IGM Biosciences (NASDAQ:IGMS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni IGM Biosciences (NASDAQ:IGMS)
Storico
Da Giu 2023 a Giu 2024